Paeds Vivas · infectious-diseases
Influenza and antiviral treatment: Viva
Branching clinical structured oral on paediatric influenza: recognising the abrupt febrile syndrome and the atypical infant presentation, choosing and justifying empiric oseltamivir, distinguishing oseltamivir from baloxavir, and managing the biphasic deterioration of secondary bacterial pneumonia.
On this page
Study tools
Target exams
Branch 1: Recognising influenza and triaging severity
The candidate should recognise the classic picture of influenza in an older child: the abrupt onset — within hours of appearing well — of high fever, dry cough, sore throat, myalgia and marked fatigue, against a background of community influenza activity. The suddenness is the clue that distinguishes influenza from the gradual, predominantly coryzal common cold, and the classroom cluster raises the pre-test probability in season. [2]
The candidate should then triage severity and risk. This child is alert and cardiovascularly stable with acceptable oxygenation, placing him in the non-severe category, but the candidate must state explicitly the features that would escalate management: respiratory distress or hypoxia, dehydration or poor feeding, altered consciousness or seizures suggesting encephalopathy, tachycardia out of proportion to fever or poor perfusion suggesting myocarditis, and a biphasic deterioration suggesting secondary bacterial pneumonia. The candidate should also establish the host risk profile — age under two, chronic lung, cardiac or neurologic disease, immunocompromise, long-term aspirin — because high-risk status lowers the threshold to treat. [2]
The examiner will probe the atypical infant presentation. The candidate should explain that an infant under two may have no localising respiratory story at all: fever, poor feeding, irritability, lethargy, apnoea or a sepsis-like picture can be the whole illness, and that influenza belongs in the differential of the unwell infant alongside bronchiolitis, sepsis and urinary infection. A low threshold to test and treat in season is what prevents the catastrophic miss. [2]
References3ShowHide
- [1]Whitley RJ; Hayden FG; Reisinger KS; et al Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J, 2001.PMID 11224828
- [2]Jain S; Kamimoto L; Bramley AM; et al Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med, 2009.PMID 19815859
- [3]Hayden FG; Sugaya N; Hirotsu N; et al Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med, 2018.PMID 30184455